Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

Anifrolumab Plus Standard of Care Reduces Long‐Term Cardiovascular Damage in Adults With Systemic Lupus Erythematosus: Findings From a Real‐World External Control Study

Saved in:
Bibliographic Details
Published in:ACR Open Rheumatology
Format: Online Article RSS Article
Published: 2026
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1871928085085945856
collection WordPress RSS
FRELIP Feed Integration
container_title ACR Open Rheumatology
description
discipline_display Rheumatology
discipline_facet Rheumatology
format Online Article
RSS Article
genre Journal Article
id rss_article:107040
institution FRELIP
journal_source_facet ACR Open Rheumatology
last_indexed 2026-07-28T03:35:35.991Z
publishDate 2026
publishDateSort 2026
record_format rss_article
spellingShingle Anifrolumab Plus Standard of Care Reduces Long‐Term Cardiovascular Damage in Adults With Systemic Lupus Erythematosus: Findings From a Real‐World External Control Study
Rheumatology
General
Rheumatology
sub_discipline_display General
sub_discipline_facet General
subject_display Rheumatology
General
Rheumatology
subject_facet Rheumatology
General
Rheumatology
title Anifrolumab Plus Standard of Care Reduces Long‐Term Cardiovascular Damage in Adults With Systemic Lupus Erythematosus: Findings From a Real‐World External Control Study
title_alt Anifrolumab más estándar de atención reduce el daño cardiovascular a largo plazo en adultos con lupus eritematoso sistémico: Hallazgos de un estudio de control externo del mundo real
L'anifrolumab plus soins standard réduit les dommages cardiovasculaires à long terme chez les adultes atteints de lupus érythémateux disséminé : résultats d'une étude de contrôle externe en conditions réelles
Anifrolumabe Mais Padrão de Cuidado Reduz Danos Cardiovasculares de Longo Prazo em Adultos com Lúpus Eritematoso Sistêmico: Descobertas de um Estudo de Controle Externo do Mundo Real
title_auth Anifrolumab Plus Standard of Care Reduces Long‐Term Cardiovascular Damage in Adults With Systemic Lupus Erythematosus: Findings From a Real‐World External Control Study
title_es_txt Anifrolumab más estándar de atención reduce el daño cardiovascular a largo plazo en adultos con lupus eritematoso sistémico: Hallazgos de un estudio de control externo del mundo real
title_fr_txt L'anifrolumab plus soins standard réduit les dommages cardiovasculaires à long terme chez les adultes atteints de lupus érythémateux disséminé : résultats d'une étude de contrôle externe en conditions réelles
title_full Anifrolumab Plus Standard of Care Reduces Long‐Term Cardiovascular Damage in Adults With Systemic Lupus Erythematosus: Findings From a Real‐World External Control Study
title_fullStr Anifrolumab Plus Standard of Care Reduces Long‐Term Cardiovascular Damage in Adults With Systemic Lupus Erythematosus: Findings From a Real‐World External Control Study
title_full_unstemmed Anifrolumab Plus Standard of Care Reduces Long‐Term Cardiovascular Damage in Adults With Systemic Lupus Erythematosus: Findings From a Real‐World External Control Study
title_pt_txt Anifrolumabe Mais Padrão de Cuidado Reduz Danos Cardiovasculares de Longo Prazo em Adultos com Lúpus Eritematoso Sistêmico: Descobertas de um Estudo de Controle Externo do Mundo Real
title_short Anifrolumab Plus Standard of Care Reduces Long‐Term Cardiovascular Damage in Adults With Systemic Lupus Erythematosus: Findings From a Real‐World External Control Study
title_sort anifrolumab plus standard of care reduces long‐term cardiovascular damage in adults with systemic lupus erythematosus: findings from a real‐world external control study
topic Rheumatology
General
Rheumatology
url https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr2.90071?af=R